Path of least resistance

Counting on a different primary endpoint in a potentially less challenging indication, Corgentech Inc. says its edifoligide E2F decoy can still be successful in an ongoing Phase III trial in coronary artery bypass graft patients, despite last week's disappointing results from another study in peripheral artery bypass graft (PBG) surgery of the leg. Meanwhile, the company expects to begin clinical testing

Read the full 612 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE